Recce Pharmaceuticals Ltd (RCE) - Cash Flow Conversion Efficiency

Latest as of June 2025: 4.429x

Based on the latest financial reports, Recce Pharmaceuticals Ltd (RCE) has a cash flow conversion efficiency ratio of 4.429x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-13.52 Million ≈ $-9.57 Million USD) by net assets (AU$-3.05 Million ≈ $-2.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Recce Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Recce Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Recce Pharmaceuticals Ltd (RCE) financial obligations for a breakdown of total debt and financial obligations.

Recce Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Recce Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
GEA Grenobl. Elect. PA:GEA	0.134x
Global Lights Acquisition Corp Ordinary Shares NASDAQ:GLACF	-0.003x
Alkindo Naratama Tbk JK:ALDO	-0.038x
OptiNose NASDAQ:OPTN	-0.027x
Flexopack Société Anonyme Commercial and Industrial Plastics Company AT:FLEXO	0.048x
Global Lights Acquisition Corp Ordinary Shares NASDAQ:GLAC	-0.003x
We & Win Development Co Ltd TW:2537	0.033x
Eimco Elecon (India) Limited NSE:EIMCOELECO	0.013x

Annual Cash Flow Conversion Efficiency for Recce Pharmaceuticals Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Recce Pharmaceuticals Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Recce Pharmaceuticals Ltd worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$-3.05 Million ≈ $-2.16 Million	AU$-20.44 Million ≈ $-14.46 Million	6.698x	+390.36%
2024-06-30	AU$-9.52 Million ≈ $-6.74 Million	AU$-13.01 Million ≈ $-9.20 Million	1.366x	-72.13%
2023-06-30	AU$-2.59 Million ≈ $-1.83 Million	AU$-12.69 Million ≈ $-8.98 Million	4.901x	+647.26%
2022-06-30	AU$10.06 Million ≈ $7.12 Million	AU$-9.01 Million ≈ $-6.38 Million	-0.896x	-133.73%
2021-06-30	AU$20.50 Million ≈ $14.51 Million	AU$-7.86 Million ≈ $-5.56 Million	-0.383x	+76.73%
2020-06-30	AU$2.31 Million ≈ $1.64 Million	AU$-3.81 Million ≈ $-2.69 Million	-1.646x	-125.56%
2019-06-30	AU$-405.60K ≈ $-286.99K	AU$-2.61 Million ≈ $-1.85 Million	6.440x	+358.34%
2018-06-30	AU$694.91K ≈ $491.70K	AU$-1.73 Million ≈ $-1.23 Million	-2.493x	+41.10%
2017-06-30	AU$590.14K ≈ $417.56K	AU$-2.50 Million ≈ $-1.77 Million	-4.233x	-825.16%
2016-06-30	AU$3.51 Million ≈ $2.49 Million	AU$-1.61 Million ≈ $-1.14 Million	-0.458x	-628.29%
2015-06-30	AU$4.71 Million ≈ $3.34 Million	AU$-296.14K ≈ $-209.54K	-0.063x	+69.36%
2014-06-30	AU$-55.74K ≈ $-39.44K	AU$11.43K ≈ $8.09K	-0.205x	--

About Recce Pharmaceuticals Ltd

AU:RCE Australia Biotechnology

Market Cap

$97.19 Million

AU$137.36 Million AUD

Market Cap Rank

#19299 Global

#634 in Australia

Share Price

AU$0.48

Change (1 day)

+0.00%

52-Week Range

AU$0.28 - AU$0.71

All Time High

AU$1.68